Search Results - "Lombard, Alan P."

The emerging role of the androgen receptor in bladder cancer by Lombard, Alan P, Mudryj, Maria

“…Men are three to four times more likely to get bladder cancer than women. The gender disparity characterizing bladder cancer diagnoses has been investigated…”
Get full text

Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer by Zhao, Jinge, Ning, Shu, Lou, Wei, Yang, Joy C, Armstrong, Cameron M, Lombard, Alan P, D'Abronzo, Leandro S, Evans, Christopher P, Gao, Allen C, Liu, Chengfei

“…The next-generation antiandrogen drugs, XTANDI (enzalutamide), ZYTIGA (abiraterone acetate), ERLEADA (apalutamide) and NUBEQA (darolutamide) extend survival…”
Get full text

Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer by Liu, Chengfei, Lou, Wei, Yang, Joy C., Liu, Liangren, Armstrong, Cameron M., Lombard, Alan P., Zhao, Ruining, Noel, Onika D. V., Tepper, Clifford G., Chen, Hong-Wu, Dall’Era, Marc, Evans, Christopher P., Gao, Allen C.

“…Protein homeostasis (proteostasis) is a potential mechanism that contributes to cancer cell survival and drug resistance. Constitutively active androgen…”
Get full text

AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer by Liu, Chengfei, Yang, Joy C, Armstrong, Cameron M, Lou, Wei, Liu, Liangren, Qiu, Xiaomin, Zou, Binhao, Lombard, Alan P, D'Abronzo, Leandro S, Evans, Christopher P, Gao, Allen C

“…The mechanisms resulting in resistance to next-generation antiandrogens in castration-resistant prostate cancer are incompletely understood. Numerous studies…”
Get full text

ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer by Lombard, Alan P, Liu, Chengfei, Armstrong, Cameron M, Cucchiara, Vito, Gu, Xinwei, Lou, Wei, Evans, Christopher P, Gao, Allen C

“…Advancements in research have added several new therapies for castration-resistant prostate cancer (CRPC), greatly augmenting our ability to treat patients…”
Get full text

Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer by Lombard, Alan P, Liu, Liangren, Cucchiara, Vito, Liu, Chengfei, Armstrong, Cameron M, Zhao, Ruining, Yang, Joy C, Lou, Wei, Evans, Christopher P, Gao, Allen C

“…Current treatments for castration resistant prostate cancer (CRPC) largely fall into two classes: androgen receptor (AR)-targeted therapies such as the…”
Get full text

Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment by Ning, Shu, Liu, Chengfei, Lou, Wei, Yang, Joy C, Lombard, Alan P, D'Abronzo, Leandro S, Batra, Neelu, Yu, Ai-Ming, Leslie, Amy R, Sharifi, Masuda, Evans, Christopher P, Gao, Allen C

“…The next-generation antiandrogen drugs such as enzalutamide and abiraterone extend survival times and improve quality of life in patients with advanced…”
Get full text

Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer by Liu, Chengfei, Armstrong, Cameron M, Lou, Wei, Lombard, Alan P, Cucchiara, Vito, Gu, Xinwei, Yang, Joy C, Nadiminty, Nagalakshmi, Pan, Chong-Xian, Evans, Christopher P, Gao, Allen C

“…Activation of the androgen receptor (AR) and its splice variants is linked to advanced prostate cancer and drives resistance to antiandrogens. The roles of AR…”
Get full text

MicroRNA‐181a promotes docetaxel resistance in prostate cancer cells by Armstrong, Cameron M., Liu, Chengfei, Lou, Wei, Lombard, Alan P., Evans, Christopher P., Gao, Allen C.

“…BACKGROUND Docetaxel is one of the primary drugs used for treating castration resistant prostate cancer (CRPC). Unfortunately, over time patients invariably…”
Get full text

Resistance mechanisms to taxanes and PARP inhibitors in advanced prostate cancer by Lombard, Alan P., Gao, Allen C.

“…The clinical landscape concerning advanced prostate cancer is rapidly changing and reaching beyond androgen deprivation therapy and androgen receptor-targeted…”
Get full text

Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer by Lombard, Alan P, Liu, Chengfei, Armstrong, Cameron M, D'Abronzo, Leandro S, Lou, Wei, Chen, Hongwu, Dall'Era, Marc, Ghosh, Paramita M, Evans, Christopher P, Gao, Allen C

“…Castration-resistant prostate cancer remains as an incurable disease. Exploiting DNA damage repair defects via inhibition of poly (ADP-ribose) polymerase…”
Get full text

IGFBP3 promotes resistance to Olaparib via modulating EGFR signaling in advanced prostate cancer by Leslie, Amy R., Ning, Shu, Armstrong, Cameron M., D’Abronzo, Leandro S., Sharifi, Masuda, Schaaf, Zachary A., Lou, Wei, Liu, Chengfei, Evans, Christopher P., Lombard, Alan P., Gao, Allen C.

“…Olaparib is a pioneering PARP inhibitor (PARPi) approved for treating castration-resistant prostate cancer (CRPC) tumors harboring DNA repair defects, but…”
Get full text

Activation of neural lineage networks and ARHGEF2 in enzalutamide-resistant and neuroendocrine prostate cancer and association with patient outcomes by Ning, Shu, Zhao, Jinge, Lombard, Alan P., D’Abronzo, Leandro S., Leslie, Amy R., Sharifi, Masuda, Lou, Wei, Liu, Chengfei, Yang, Joy C., Evans, Christopher P., Corey, Eva, Chen, Hong-Wu, Yu, Aiming, Ghosh, Paramita M., Gao, Allen C.

“…Background Treatment-emergent neuroendocrine prostate cancer (NEPC) after androgen receptor (AR) targeted therapies is an aggressive variant of prostate cancer…”
Get full text

Activation of the ABCB1 Amplicon in Docetaxel- and Cabazitaxel-Resistant Prostate Cancer Cells by Lombard, Alan P, Lou, Wei, Armstrong, Cameron M, D'Abronzo, Leandro S, Ning, Shu, Evans, Christopher P, Gao, Allen C

“…Docetaxel and cabazitaxel-based taxane chemotherapy are critical components in the management of advanced prostate cancer. However, their efficacy is hindered…”
Get full text

LX1 Dual Targets AR Variants and AKR1C3 in Advanced Prostate Cancer Therapy by Ning, Shu, Armstrong, Cameron M., Xing, Enming, Leslie, Amy R., Gao, Richard Y., Sharifi, Masuda, Schaaf, Zachary A., Lou, Wei, Han, Xiangrui, Xu, Desiree H., Yang, Rui, Cheng, Jeffrey, Mohammed, Shabber, Mitsiades, Nicholas, Liu, Chengfei, Lombard, Alan P., Wu, Chun-Yi, Cheng, Xiaolin, Li, Pui-Kai, Gao, Allen C.

“…Abstract The development of resistance to current standard-of-care treatments, such as androgen receptor (AR) targeting therapies, remains a major challenge in…”
Get full text

Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer by Armstrong, Cameron M, Liu, Chengfei, Liu, Liangren, Yang, Joy C, Lou, Wei, Zhao, Ruining, Ning, Shu, Lombard, Alan P, Zhao, Jinge, D'Abronzo, Leandro S, Evans, Christopher P, Li, Pui-Kai, Gao, Allen C

“…Most patients with prostate cancer receiving enzalutamide or abiraterone develop resistance. Clinical evidence indicates that serum levels of…”
Get full text

ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling by Liu, Chengfei, Armstrong, Cameron M., Ning, Shu, Yang, Joy C., Lou, Wei, Lombard, Alan P., Zhao, Jinge, Wu, Chun-Yi, Yu, Aiming, Evans, Christopher P., Tepper, Clifford G., Li, Pui-kai, Gao, Allen C.

“…Targeting androgen signaling with the second-generation anti-androgen drugs, such as enzalutamide (Enza), abiraterone (Abi), apalutamide (Apal), and…”
Get full text

Olaparib-Induced Senescence Is Bypassed through G2-M Checkpoint Override in Olaparib-Resistant Prostate Cancer by Lombard, Alan P, Armstrong, Cameron M, D'Abronzo, Leandro S, Ning, Shu, Leslie, Amy R, Sharifi, Masuda, Lou, Wei, Evans, Christopher P, Dall'Era, Marc, Chen, Hong-Wu, Chen, Xinbin, Gao, Allen C

“…PARP inhibition represents the dawn of precision medicine for treating prostate cancer. Despite this advance, questions remain regarding the use of PARP…”
Get full text

Depletion of androgen receptor low molecular weight isoform reduces bladder tumor cell viability and induces apoptosis by Katleba, Kimberley, Lombard, Alan P., Tsamouri, Maria-Malvina, Baek, Han Bit, Nishida, Kristine S., Libertini, Stephen J., Platero, Alexander J., Ma, Ai-Hong, Pan, Chong-xian, Ghosh, Paramita M., Mudryj, Maria

“…Bladder cancer (BlCa) exhibits a gender disparity where men are three times more likely to develop the malignancy than women suggesting a role for the androgen…”
Get full text

Therapeutic Resistance Models and Treatment Sequencing in Advanced Prostate Cancer by Schaaf, Zachary A, Ning, Shu, Leslie, Amy R, Sharifi, Masuda, Han, Xianrui, Armstrong, Cameron, Lou, Wei, Lombard, Alan P, Liu, Chengfei, Gao, Allen C

“…Current common treatments for castration-resistant prostate cancer (CRPC) typically belong to one of three major categories: next-generation anti-androgen…”
Get full text